Alexo Therapeutics to Present ALX148 Preclinical Data at the 59th American Society of Hematology Annual Meeting (ASH)
DUBLIN, Ireland and SOUTH SAN FRANCISCO, Calif. – November 13, 2017 – Alexo Therapeutics, a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint mechanism exploited by cancer cells to evade the immune system, today announced that ALX148 preclinical results have been selected for an oral presentation at the 59th ASH Annual Meeting & Exposition, Dec. 9-12, 2017 in Atlanta, Georgia.
Oral Presentation Information
Title: ALX148 Is a High Affinity SIRPα Fusion Protein That Blocks CD47, Enhances the Activity of Anti-Cancer Antibodies and Checkpoint Inhibitors, and Has a Favorable Safety Profile in Preclinical Models
Session Name: 625. Lymphoma: Pre-Clinical—Chemotherapy and Biologic Agents: New Tools and Emerging Immune-Modulatory Approaches for Non-Hodgkin’s Lymphomas
Session Date: Saturday, December 9, 2017
Presentation Time: 10:15 am ET
Room: Georgia World Congress Center, Building C, Level 1, C101 auditorium
Publication Number: 112
About Alexo Therapeutics
Alexo Therapeutics is a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint mechanism exploited by cancer cells to evade the immune system. Our lead candidate, ALX148, is a fusion protein that comprises an engineered high affinity CD47 binding domain of SIRPα linked to an inactive Fc region of human immunoglobulin. ALX148 is designed to enhance the efficacy of antibody-based therapies and is in clinical development for a broad range of tumor types.
Karen Sharma or Shai Biran, Ph.D.
MacDougall Biomedical Communications